title: Initiation of buprenorphine during incarceration and retention in treatment upon release.
abstract: We report here on a feasibility study of initiating buprenorphine/naloxone prior to release from incarceration and linking participants to community treatment providers upon release. The study consisted of a small number of Rhode Island (RI) prisoners (N = 44) diagnosed with opioid dependence. The study design is a single arm, open-label pilot study with a 6-month follow up interview conducted in the community. However, a natural experiment arose during the study comparing pre-release initiation of buprenorphone/naloxone to initiation post-release. Time to post-release prescriber appointment (mean days) for initiation of treatment outside Rhode Island Department of Corrections (RIDOC) versus inside RIDOC was 8.8 and 3.9, respectively (p = .1). Median post release treatment duration (weeks) for outside RIDOC versus inside RIDOC was 9 and 24, respectively (p = .007). We conclude that initiating buprenorphine/naloxone prior to release from incarceration may increase engagement and retention in community-based treatment.
authors.affiliation: The Miriam Hospital, Providence, RI, USA. nzaller@lifespan.org
authors.forename: Nickolas
authors.initials: N
authors.lastname: Zaller
authors.forename: Michelle
authors.initials: M
authors.lastname: McKenzie
authors.forename: Peter D
authors.initials: PD
authors.lastname: Friedmann
authors.forename: Traci C
authors.initials: TC
authors.lastname: Green
authors.forename: Samuel
authors.initials: S
authors.lastname: McGowan
authors.forename: Josiah D
authors.initials: JD
authors.lastname: Rich
mesh_terms: D000328:Adult; D002047:Buprenorphine / Q000008:administration & dosage*; D000069479:Buprenorphine, Naloxone Drug Combination; D003153:Community Health Services / Q000379:methods; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009270:Naloxone / Q000008:administration & dosage*; D058850:Opiate Substitution Treatment / Q000379:methods; D009293:Opioid-Related Disorders / Q000534:rehabilitation*; D010349:Patient Compliance; D010865:Pilot Projects; D011329:Prisoners; D012237:Rhode Island; D013997:Time Factors
chemical_list: D000069479:Buprenorphine, Naloxone Drug Combination; D009270:Naloxone; D002047:Buprenorphine
references.citation: Ann Med Interne (Paris). 2001 Apr;152 Suppl 3:IS26-36
references.pmid: 11435992
references.citation: Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S59-77
references.pmid: 12738351
references.citation: Drug Alcohol Depend. 2012 Jan 1;120(1-3):190-5
references.pmid: 21862241
references.citation: J Subst Abuse Treat. 2007 Apr;32(3):239-54
references.pmid: 17383549
references.citation: Int J Environ Res Public Health. 2009 Feb;6(2):787-97
references.pmid: 19440415
references.citation: Drug Alcohol Depend. 2000 Dec 22;61(1):85-94
references.pmid: 11064186
references.citation: Addict Disord Their Treat. 2011 Dec;10(4):199-200
references.pmid: 22121339
references.citation: Subst Abus. 2012;33(1):40-7
references.pmid: 22263712
references.citation: J Subst Abuse Treat. 1992;9(3):199-213
references.pmid: 1334156
references.citation: Arch Intern Med. 2011 Mar 14;171(5):425-31
references.pmid: 21403039
references.citation: Am J Public Health. 2006 Jun;96(6):974-8
references.pmid: 16449578
references.citation: J Urban Health. 2005 Sep;82(3):411-9
references.pmid: 15917502
references.citation: Behav Sci Law. 2011 Nov-Dec;29(6):829-45
references.pmid: 22086665
references.citation: Pain Med. 2010 Jul;11(7):1078-91
references.pmid: 20545875
references.citation: Drug Alcohol Depend. 2007 Apr 17;88(1):75-8
references.pmid: 17055191
references.citation: Drug Alcohol Depend. 2011 Dec 15;119(3):172-8
references.pmid: 21782352
references.citation: J Offender Rehabil. 2010 Feb;49(2):91-109
references.pmid: 20473351
references.citation: Curr Drug Abuse Rev. 2011 Mar;4(1):28-41
references.pmid: 21466501
references.citation: J Addict Med. 2007 Sep;1(3):126-32
references.pmid: 21768947
references.citation: Am J Psychiatry. 2001 Aug;158(8):1200-4
references.pmid: 11481150
references.citation: Addiction. 1995 Apr;90(4):545-54
references.pmid: 7773117
references.citation: N Engl J Med. 2007 Jan 11;356(2):157-65
references.pmid: 17215533
references.citation: Clin Pharmacokinet. 2005;44(7):661-80
references.pmid: 15966752
references.citation: Clin Infect Dis. 2006 Dec 15;43 Suppl 4:S197-215
references.pmid: 17109307
references.citation: J Psychoactive Drugs. 1998 Jul-Sep;30(3):225-9
references.pmid: 9798787
references.citation: Drug Alcohol Depend. 2005 Mar 7;77(3):269-81
references.pmid: 15734227
references.citation: J Addict Med. 2011 Sep;5(3):175-80
references.pmid: 21844833
references.citation: Cochrane Database Syst Rev. 2008 Apr 16;(2):CD002207
references.pmid: 18425880
references.citation: BMJ. 1995 Oct 28;311(7013):1135-6
references.pmid: 7580709
references.citation: Am J Addict. 2004;13 Suppl 1:S17-28
references.pmid: 15204673
references.citation: Drug Alcohol Depend. 2009 Jan 1;99(1-3):222-30
references.pmid: 18930603
references.citation: Clin Pharmacol Ther. 1994 May;55(5):569-80
references.pmid: 8181201
references.citation: J Subst Abuse Treat. 2010 Jul;39(1):41-50
references.pmid: 20434868
references.citation: J Psychoactive Drugs. 2010 Sep;42(3):339-46
references.pmid: 21053756
references.citation: JAMA. 2001 Jan 3;285(1):45
references.pmid: 11150107
references.citation: Subst Abus. 2012;33(1):19-29
references.pmid: 22263710
references.citation: J Nerv Ment Dis. 1992 Feb;180(2):101-10
references.pmid: 1737971
references.citation: NIDA Res Monogr. 1992;118:8-30
references.pmid: 1620228
references.citation: Drug Alcohol Depend. 2009 Nov 1;105(1-2):83-8
references.pmid: 19625142
references.citation: Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S29-37
references.pmid: 12738348